

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, New Zealand, South Africa or the United States or in any other jurisdictions where such offer pursuant to legislation and regulations in such relevant jurisdictions would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled "Important notice" at the end of this announcement and in the tender offer document which has been published on GBO's website for the Offer (www.gbo-vigmed.se/en/).



Press release

3 May 2017

GBO declares its offer to the shareholders of Vigmed unconditional and completes the offer

On 27 February 2017, Greiner Bio-One GmbH ("GBO") announced a recommended public offer to the shareholders of Vigmed Holding AB (publ) ("Vigmed") to tender all shares in Vigmed to GBO (the "Offer") for a consideration of SEK 1.00 in cash per share. On 13 April 2017, the Offer consideration was increased to SEK 1.20 in cash per share.

The shares tendered in the Offer at the end of the extended acceptance period on 27 April 2017 amount to in aggregate 44,545,399 shares in Vigmed, corresponding to 67.75 percent of the total number of outstanding shares and votes in Vigmed.

As previously communicated, completion of the Offer is conditional upon, inter alia, the Offer being accepted to such extent that GBO becomes the owner of more than 90 percent of all shares in Vigmed. GBO has decided to waive this condition. Accordingly, all of the conditions for completion of the Offer have been satisfied or waived. GBO declares the Offer unconditional and will complete the Offer. Settlement in respect of shares in Vigmed duly tendered by 27 April 2017 is expected to be initiated on or about 5 May 2017.

To provide the remaining shareholders in Vigmed more time to accept the Offer, GBO has decided to further extend the acceptance period until and including 17 May 2017 at 5:00 p.m. CEST. Settlement in respect of shares in Vigmed tendered during such further extended acceptance period is expected to be initiated on or about 24 May 2017. The acceptance period will not be extended further.

Other than the shares in Vigmed acquired through the Offer as set out above, GBO does not currently own or control any shares or financial instruments that provide a financial exposure equivalent to a holding of shares in Vigmed.

"We are excited to become the main shareholder of Vigmed. As a long-term shareholder GBO intends to engage in the challenge of developing Vigmed's business and product portfolio, including to financially support Vigmed in the significant capital injections that will be required to satisfy the immediate need of liquidity and to realize Vigmed's long-term prospects. A significant majority of the shareholders have appreciated GBO's attractive offer and have now sold their shares to GBO. In order to provide the remaining shareholders of Vigmed the

opportunity to benefit from GBO's offer, we have made a final extension of the acceptance period for an additional two weeks", said Rainer Perneker, CEO of the Greiner Bio-One group.

Greiner Bio-One GmbH

For additional information, please contact:

Georg Heftberger, Chief Financial Officer, Greiner Bio-One GmbH, tel. +43 664 8841 0683

Eric Tapper, Hallvarsson & Halvarsson, tel. +46 8 407 21 80

For information and documentation regarding the Offer, please visit: www.gbo-vigmed.se/en/

This press release was submitted for publication on 3 May 2017 at 8:00 a.m. CEST.

Important notice

The Offer is not being made, directly or indirectly, in or into Australia, Canada, Hong Kong, New Zealand, South Africa or the United States by use of mail or any other means or instrumentality (including, without limitation, facsimile transmission, electronic mail, telex, telephone and the Internet) of interstate or foreign commerce, or of any facility of national security exchange, of Australia, Canada, Hong Kong, New Zealand, South Africa or the United States, and the Offer cannot be accepted by any such use, means, instrumentality or facility of, or from within, Australia, Canada, Hong Kong, New Zealand, South Africa or the United States. Accordingly, this press release and any documentation relating to the Offer are not being and should not be sent, mailed or otherwise distributed or forwarded in or into Australia, Canada, Hong Kong, New Zealand, South Africa or the United States.

This press release is not being, and must not be, sent to shareholders with registered addresses in Australia, Canada, Hong Kong, New Zealand, South Africa or the United States. Banks, brokers, dealers and other nominees holding shares for persons in Australia, Canada, Hong Kong, New Zealand, South Africa or the United States must not forward this press release or any other document received in connection with the Offer to such persons.

Statements in this press release relating to future status or circumstances, including statements regarding future performance, growth and other trend projections and the other benefits of the Offer, are forward-looking statements. These statements may generally, but not always, be identified by the use of words such as "anticipates", "intends", "expects", "believes", or similar expressions. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There can be no assurance that actual results will not differ materially from those expressed or implied by these forward-looking statements due to many factors, many of which are outside the control of Greiner Bio-One GmbH. Any such forward-looking statements speak only as of the date on which they are made and Greiner Bio-One GmbH has no obligation (and undertakes no such obligation) to update or revise any of them, whether as a result of new information, future events or otherwise, except for in accordance with applicable laws and regulations.